AMENDMENT TO
RULES COMMITTEE PRINT 118–10
OFFERED BY MR. BUCK OF COLORADO

Page 1033, after line 14, add the following new sec-
tion:

SEC. 18. SENSE OF CONGRESS REGARDING MDMA-AS-
SISTED THERAPY AS TREATMENT FOR PTSD.

It is the sense of Congress that—

(1) 3,4-Methylenedioxy-methamphetamine-as-
sisted therapy (in this section referred to as
“MDMA-AT”) should be recognized as a treatment
for post-traumatic stress disorder (in this section re-
ferred to as “PTSD”);

(2) MDMA-AT has shown great scientific
promise for treating complex, chronic PTSD, as evi-
denced by MDMA-AT being designated as a break-
through therapy under section 506 of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C. 356) in
2017 for its use in conjunction with talk therapy to
treat PTSD;

(3) the potential of MDMA-AT was confirmed
in 2021, when the world’s first phase 3 randomized,
double-blind, placebo-controlled trial found that after
3 MDMA-AT sessions, 67 percent of participants no longer qualified for a PTSD diagnosis, and 88 percent experienced a clinically significant reduction in symptoms;

(4) additional phase 3 clinical trial results further confirmed these findings, and full approval of MDMA-AT under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) is now expected in 2024;

(5) thanks to significant private funding, the Nation’s leading academic institutions (including Johns Hopkins University, Yale University, Harvard University, and Stanford University) and governmental institutions (including the Department of Veterans Affairs, the National Institutes of Health, and the Food and Drug Administration) have researched MDMA-AT’s potential for treating PTSD for the past 2 decades; and

(6) MDMA-AT is a worthwhile investment in the mental health of the Nation’s veterans.